- Home
- RDVT vs IMNM Comparison
RDVT vs IMNM Comparison
Compare RDVT & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDVT
- IMNM
- Stock Information
- Founded
- RDVT 2017
- IMNM 2006
- Country
- RDVT United States
- IMNM United States
- Employees
- RDVT N/A
- IMNM N/A
- Industry
- RDVT Computer Software: Prepackaged Software
- IMNM Medicinal Chemicals and Botanical Products
- Sector
- RDVT Technology
- IMNM Health Care
- Exchange
- RDVT Nasdaq
- IMNM Nasdaq
- Market Cap
- RDVT 538.6M
- IMNM 542.6M
- IPO Year
- RDVT N/A
- IMNM 2020
- Fundamental
- Price
- RDVT $36.72
- IMNM $7.91
- Analyst Decision
- RDVT
- IMNM Strong Buy
- Analyst Count
- RDVT 0
- IMNM 6
- Target Price
- RDVT N/A
- IMNM $26.00
- AVG Volume (30 Days)
- RDVT 79.2K
- IMNM 1.7M
- Earning Date
- RDVT 05-07-2025
- IMNM 05-13-2025
- Dividend Yield
- RDVT 0.81%
- IMNM N/A
- EPS Growth
- RDVT N/A
- IMNM N/A
- EPS
- RDVT 0.50
- IMNM N/A
- Revenue
- RDVT $75,189,000.00
- IMNM $9,041,000.00
- Revenue This Year
- RDVT $15.93
- IMNM N/A
- Revenue Next Year
- RDVT $13.85
- IMNM $1,259.12
- P/E Ratio
- RDVT $73.63
- IMNM N/A
- Revenue Growth
- RDVT 24.89
- IMNM N/A
- 52 Week Low
- RDVT $16.56
- IMNM $5.15
- 52 Week High
- RDVT $43.44
- IMNM $19.07
- Technical
- Relative Strength Index (RSI)
- RDVT 47.11
- IMNM 55.28
- Support Level
- RDVT $36.16
- IMNM $6.96
- Resistance Level
- RDVT $37.93
- IMNM $7.56
- Average True Range (ATR)
- RDVT 2.26
- IMNM 0.69
- MACD
- RDVT 0.02
- IMNM 0.26
- Stochastic Oscillator
- RDVT 64.23
- IMNM 98.22
About RDVT Red Violet Inc.
Red Violet Inc is a software and services company. It specializes in big data analysis, providing cloud-based, mission-critical information solutions to enterprises in a variety of industries. Through its CORE data fusion platform, it provides mission-critical information about individuals, businesses and assets.
About IMNM Immunome Inc.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.